1. DOP47 Real World Evidence on the effectiveness of ustekinumab in Crohn's Disease: Induction phase results from the prospective, observational RUN-CD Study. (27th May 2021) Authors: Bokemeyer, B; Plachta-Danielzik, S; Di Giuseppe, R; Mohl, W; Teich, N; Hoffstadt, M; Schweitzer, A; von der Ohe, M; Gauss, A; Atreya, R; Krause, T; Blumenstein, I; Höchstödter, J; Hartmann, P; Schreiber, S Journal: Journal of Crohn's and colitis Issue: Volume 15(2021)Supplement 1 Page Start: S083 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. DOP77 Comparative real-world effectiveness and persistence of vedolizumab versus anti-TNF therapy in biologic-naïve patients with Crohn′s Disease with Propensity Score adjustment: Maintenance phase results at week-52 from the prospective VEDOIBD study. (21st January 2022) Authors: Di Giuseppe, R; Plachta-Danielzik, S; Bokemeyer, B; Efken, P; Mohl, W; Hoffstadt, M; Krause, T; Schweitzer, A; Schnoy, E; Atreya, R; Teich, N; Trentmann, L; Ehehalt, R; Franzenburg, S; Hartmann, P; Schreiber, S Journal: Journal of Crohn's and colitis Issue: Volume 16(2022)Supplement 1 Page Start: i120 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗